A Variant In the ABO Gene Explains the Variation in Soluble E-Selectin Levels—Results from Dense Genotyping in Two Independent Populations

Mahir Karakas1,*, Jens Baumert2,9, Marcus E. Kleber1,3, Barbara Thorand2, Dhayana Dallmeier1, Günther Silbernagel4, Tanja B. Grammer3, Wolfgang Rottbauer1, Christa Meisinger2, Thomas Illig5,6, Winfried März2,7,8, Wolfgang Koenig1*

1 Department of Internal Medicine II – Cardiology, University of Ulm Medical Centre, Ulm, Germany, 2 Institute of Epidemiology II, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany, 3 Mannheim Institute of Public Health, Social and Preventive Medicine, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany, 4 Division of Endocrinology, Diabetology, Nephrology, Vascular Disease, and Clinical Chemistry, Department of Internal Medicine, Eberhard-Karls-University Tübingen, Tübingen, Germany, 5 Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany, 6 Hannover Unified Biobank, Hannover Medical School, Hannover, Germany, 7 Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria, 8 Synlab Academy, Synlab Services GmbH, Mannheim, Germany

Abstract

Background: Elevated soluble (s) E-selectin levels have been associated with various cardiovascular diseases. Recently, genetic variants in the ABO blood group have been related to E-selectin levels in a small cohort of patients with type 1 diabetes. We evaluated whether this association is reproducible in two large samples of Caucasians.

Methodology/ Principal Findings: Data of the present study was drawn from the population-based MONICA/KORA Augsburg study (n = 1,482) and the patient-based LURIC study (n = 1,546). A high-density genotyping array (50K IBC Chip) containing single-nucleotide polymorphisms (SNPs) from E-selectin candidate genes selected on known biology of E-selectin metabolism, mouse genetic studies, and human genetic association studies, was used for genotyping. Linear regression analyses with adjustment for age and sex (and survey in KORA) were applied to assess associations between gene variants and sE-selectin concentrations. A number of 12 SNPs (in KORA) and 13 SNPs (in LURIC), all from the ABO blood group gene, were significantly associated with the log-transformed concentration of E-selectin. The strongest association was observed for rs651007 with a change of log-transformed sE-selectin per one copy of the minor allele of −0.37 ng/ml (p = 1.87 × 10−10) in KORA and −0.35 ng/ml (p = 5.11 × 10−84) in LURIC. Inclusion of rs651007 increased the explained sE-selectin variance by 0.256 in KORA and 0.213 in LURIC. All SNPs had minor allele frequencies above 20% showing a substantial gene variation.

Conclusions/ Significance: Our findings in two independent samples indicate that the genetic variants at the ABO locus affect sE-selectin levels. Since distinct genome-wide association studies linked the ABO gene with myocardial infarction (MI) in the presence of coronary atherosclerosis and with coronary artery disease, these findings may not only enhance our understanding of adhesion molecule biology, but may also provide a focus for several novel research avenues.

Introduction

Atherosclerosis involves the recruitment and transendothelial migration of inflammatory cells into vessel walls, which is mediated by cellular adhesion molecules [1]. This multistep process of the interaction between leukocytes and endothelial cells leading to T cell migration into vessels is initiated by selectins, which by ligand interactions allow lymphocytes rolling along the endothelial lining, thereby initiating atherosclerosis. E-selectin is a
cell adhesion molecule expressed only on endothelial cells activated by cytokines [2]. The local release of the cytokines IL-1 and TNF-α by damaged cells induces the over-expression of E-selectin on endothelial cells of nearby blood vessels. Circulating concentrations of sE-selectin have been associated with cardiometabolic diseases like diabetes, carotid atherosclerosis and coronary heart disease (CHD), and also with the metastatic potential of some cancers including colorectal cancer and recurrences [3,4]. Since recently genetic variants in the ABO blood group have been related to E-selectin levels in a small cohort of patients with type 1 diabetes [5], we aimed to evaluate whether this association is reproducible in two large samples of Caucasians.

Methods

Study population

The MONICA/KORA (MONItoring of trends and determinants in Cardiovascular disease/ Cooperative Health Research in the Region of Augsburg/Augsburg study is a series of population-based surveys conducted in the region of Augsburg in Southern Germany [6,7]. The data for the present study was drawn from a subcohort randomly selected by sex and survey from surveys S1 to S3 conducted between 1984 and 1995 [8,9] and named KORA throughout the manuscript. After exclusion of subjects with no information on rsE-selectin concentrations or IBC 50K Chip genotype data or with individual call rates <0.95, the study population for KORA consisted of 1,482 participants (811 men, 671 women) aged 35 to 74 years. All participants were from European ancestry.

The Ludwigshafen Risk and Cardiovascular Health (LURIC) study consists of 3,316 Caucasian patients who were referred for coronary angiography to a tertiary care center in southwestern Germany [6,7]. The data for the present study was drawn from a subcohort randomly selected by sex and survey from surveys S1 to S3 conducted between 1997 and 2000 [10]. After exclusion of subjects with no information on rsE-selectin concentrations or IBC 50K Chip genotype data or with individual call rates <0.95, the study population for LURIC consisted of 1,546 participants (1084 men, 462 women) aged 17 to 92 years. In both studies, blood samples for phenotype and genotype assessment was ascertained at the same time as well as all other covariates.

Ethics Statement

The MONICA/KORA study was approved by the local authorities and performed according to the Declaration of Helsinki [11]. For the LURIC study, the “Arztekammer Rheinland-Pfalz” gave ethical approval. Written informed was obtained from all study participants in the MONICA/KORA and LURIC study.

Phenotype measurements

In KORA, E-selectin concentrations were measured with commercially available enzyme-linked immunosorbent assays (R&D Systems, Abington, UK). The intra- and inter-assay coefficients of variation of quality control test were 3.3% and 6.3%. In LURIC, sE-selectin concentrations were measured using the Human sE-selectin assay (R&D Systems GmbH, Wiesbaden, Germany) on a Rosys Plato. In both studies, the distribution of sE-selectin concentrations was skewed to the right and therefore (natural) log-transformed to reach an approximately normal distribution. Details regarding sE-selectin measurements for both studies are given in Table S1.

Genotyping

In both studies, SNPs were genotyped within the HumanCVD Genotyping Kit (IBC 50K Chip) as suggested by the manufacturer (Illumina, Inc., San Diego, USA). The genotyping was carried out using the CVD-Uppen_phase1 manifest with the Beadstudio software (Genotyping module v.3.2.29, no call threshold 0.15) in KORA, and using the CVD-Uppen_phase2 manifest in LURIC. SNPs with minor allele frequency <0.01 and SNP call rate <0.98 were excluded in both studies before the analyses leading to an overall number of SNPs of 30,984 in KORA and 35,980 in LURIC. Details of genotyping are given in Table S1.

The blood samples for phenotype and genotype assessment was ascertained at the same time as well as the other covariates.

Analytical interference analysis

Blood group A plasma was mixed 1:1 or 1:2 with a monoclonal anti-A antibody (Ortho-Clinical Diagnostics, Rochester NY), and incubated 10 minutes or 60 minutes at room temperature, or 60 minutes or 12 hours at 4°C before assaying sE-selectin levels by standard technique [12]. To exclude the possibility that the antibody itself interfered with the assay, the same procedure was repeated with plasma from O blood group individuals. Finally, plasma from O group individuals, which contains both anti-A and anti-B polyclonal antibodies, was mixed with plasma from A group individuals in 1:1 ratio, again with incubation as above and measurement of sE-selectin concentrations.

Statistical analysis

In both studies, a linear regression with adjustment for age and sex (and additionally for survey in KORA) was performed using log-transformed sE-selectin as a continuous trait and assuming an additive genetic model. Moreover, a multiple linear regression with additional adjustment for BMI, smokers, actual hypertension, history of CHD, history of diabetes, total cholesterol and HDL-C was performed in both studies. Furthermore, a conditional analysis was performed by additionally adjusting for potential top regions.

Table 1. Description of the study population.

|                | KORA   | LURIC  |
|----------------|--------|--------|
| Number of participants | 1,482  | 1,546  |
| Age (years)      | 52.5 (10.5) | 62.5 (10.9) |
| Male sex (%)     | 54.7    | 70.1    |
| BMI (kg/m²)      | 27.2 (4.0) | 27.2 (3.9) |
| Smokers (%)      | 25.4    | 19.0    |
| Systolic blood pressure (mmHg) | 134.4 (19.4) | 141.9 (23.6) |
| Diastolic blood pressure (mmHg) | 81.7 (11.2) | 80.7 (11.3) |
| Hypertension (%) | 42.9    | 72.5    |
| History of CHD (%) | 2.4     | 78.8    |
| History of diabetes (%) | 5.5     | 37.8    |
| Total cholesterol (mg/dl) | 237.9 (44.4) | 192.6 (37.9) |
| HDL-C (mg/dl)    | 56.0 (16.7) | 38.6 (10.7) |
| Lipid-lowering medication (%) | 3.58 | 46.6 |
| sE-selectin (ng/ml)** | 53.7 (39.2–69.3) | 34.0 (24.5–44.4) |
| Log(sE-selectin) (ng/ml) | 3.96 (0.44) | 3.50 (0.46) |

Values denote %, in case of continuous variable, mean (standard deviation) is given.

*only n = 1,477 subjects; ** Median (lower-upper quartile).

doi:10.1371/journal.pone.0051441.t001
For SNPs on chromosome 23, adjustments were made without sex. The association analyses were done by the genetic-statistical software PLINK [http://pngu.mgh.harvard.edu/purcell/plink] [13].

The significance threshold was set to $2.4 \times 10^{-6}$ to account for multiple testing based on about 20,500 independent tests after accounting for linkage disequilibrium (pruned dataset) with assuming a false-positive rate of 5% and be has been used in other studies utilizing the same genotyping array [14,15].

**Results**

**Study description**

Overall, about 3,000 participants were included in the present analysis: 1,482 from KORA and 1,546 from LURIC. The distribution of basic characteristics for both studies is shown in Table 1. Subjects from LURIC were older, with a mean age of 62.5 years (standard deviation 10.9) compared to subjects from KORA (mean age 52.5 years ±10.5) and were more frequently males (70.1% versus 54.7%). The median sE-selectin concentration was lower in LURIC than in KORA (34.0 ng/ml ±22.1 versus 53.7 ng/ml ±29.1).
Association analyses

The associations between IBC 50K Chip array SNPs and sE-selectin levels are displayed as Manhattan plots in Figure 1a (for KORA) and 1 b (for LURIC) by showing the p values for each chromosome and position on a log-scale. The respective Q-Q plots are shown in Figure 2. The genomic inflation factor was 1.10 in KORA, and 1.06 in LURIC.

These age and sex-adjusted association analyses revealed 12 SNPs in KORA and 13 SNPs in LURIC which had p values below the significance threshold of $5 \times 10^{-6}$ and were in both studies all located in the ABO blood group gene (ABO) on chromosome 9. All SNPs had minor allele frequencies above 20% showing a substantial gene variation. An additional adjustment for BMI, smokers, actual hypertension, history of CHD, history of diabetes, total cholesterol and HDL-C revealed very similar beta estimates and p values for rs651007 (KORA: $-0.364 \ (SE \ 0.015)$ and p value $3.64 \times 10^{-10}$, LURIC: $-0.353 \ (SE \ 0.016)$ and p value $4.72 \times 0.03$) as in the age- and sex-adjusted regression analyses. As shown in Table 2, the strongest association was observed in both studies for rs651007, with a change of log-transformed E-selectin concentration per one copy of the minor allele of $-0.37 \ ng/ml \ (p = 1.87 \times 10^{-103})$ in KORA and $-0.35 \ ng/ml \ (p = 5.11 \times 10^{-84})$ in LURIC. In both studies, the model fit assessed by the $R^2$ increased strongly from the model without rs651007 to the model with rs651007: from 0.044 to 0.300 for KORA, and from 0.021 to 0.234 for LURIC meaning $R^2$ increases of 0.256 and 0.213.

The multiple-adjusted regression analyses revealed very similar associations for rs651007 in both studies, as in the age- and sex-adjusted regression analyses (KORA: $-0.36, \ p = 3.64 \times 10^{-10}$, LURIC: $-0.35, \ p = 4.72 \times 10^{-103}$).

To assess whether other SNPs might be significantly associated with log-transformed sE-selectin concentrations independently of rs651007, we conducted a conditional analysis, i.e. an analysis additionally adjusting for rs651007. These analyses found no other associated SNP in both studies, as all SNPs were not significantly associated with log-transformed E-selectin concentrations: the beta estimates attenuated substantially for all SNPs with p values between 0.0002 and 0.775 in KORA and between 0.00006 and 0.593 in LURIC.

Analytical interference analysis

Although E-selectin is not known to bear the ABO histo-blood group antigen, this possibility could not be ruled out. We therefore excluded the possibility that the association between A histo-blood group antigen and lower sE-selectin was the consequence of a lower affinity of the antibodies used in the sE-selectin assay for E-selectin carrying the A antigen. We thus hypothesized that blocking the A antigen sites with either polyclonal or monoclonal antibodies would result in lower sE-selectin values if E-selectin does indeed carry ABO histo-blood group antigen and if the A antigen is located in the proximity of one of the two antibody binding sites used by the immunoassay. No differential effects of

---

**Table 2. Association of the top SNP rs651007 with log-transformed sE-selectin, adjusted for age and sex (and additionally for survey in KORA).**

|                | KORA               | LURIC              |
|----------------|--------------------|--------------------|
| Number of participants | 1,479*             | 1,543*             |
| SNP            | rs651007           | rs651007           |
| Position (Locus) | 135143696 (ABO)    | 135143696 (ABO)    |
| Chromosome     | 9                  | 9                  |
| Alleles major > minor | G>A                | G>A                |
| Minor allele frequency | 22.1%               | 26.0%              |
| Beta estimation (standard error) | $-0.373 \ (0.016)$ | $-0.347 \ (0.017)$ |
| $P$ value      | $1.87 \times 10^{-103}$ | $5.11 \times 10^{-84}$ |
| Change in $R^2$ | 0.256              | 0.213              |

*Coding allele was the minor allele.

*For three subjects in KORA and in LURIC, information on rs651007 was missing.

**Change in $R^2$ of age- and sex-adjusted models (+ survey in KORA) with and without rs651007.

doi:10.1371/journal.pone.0051441.t002
the mixing procedures were observed suggesting that the A blood group antigen was not interfering with measurement of sE-selectin levels (data not shown).

**Discussion**

In these analyses we could confirm previous much smaller studies that were mainly conducted in cohorts with diabetes, and extend this association to healthy subjects and patients with CHD [5]. Using dense-genotyping in two large independent populations, our findings indicate that sE-selectin concentrations are mainly determined by genetic variants at the ABO locus. Regarding the top SNP, sE-selectin concentrations decreased in both studies per one copy of the minor allele. In both studies, the model fit assessed by the R² increased strongly after addition of rs651007, and conditional analysis revealed that remaining SNPs are not independently associated with sE-selectin levels, indicating that variance in sE-selectin concentrations were mainly explained by rs651007 only. We tested the interaction of rs651007 and diabetes on E-selectin and found no modifications of the associations seen by p values for interaction of 0.52 in KORA and 0.49 in LURIC. Therefore, it can be concluded that the association between rs651007 and sE-selectin was not modified by diabetic condition. Like all SNPs found to be significantly associated with variation in sE-selectin levels in our study, the top SNP rs651007 is located within the ABO gene, which encodes a glycosyltransferase that transfers sugar residues to the H antigen and thereby determines the ABO blood group [16]. The main SNP rs651007 is located upstream. The eQTL – SNP-Gene analysis showed no effect of rs651007 on ABO expression. It has been shown that the A1 subtype, which is perfectly tagged by the minor allele of SNP rs651007 on ABO expression. It has been hypothesized that the increased glycosyltransferase activity in individuals carrying the A1 allele might have an effect on the production and clearance of adhesion molecules, thereby influencing their levels in circulation [10]. Furthermore, studies from the field of molecular biology indicated that leukocytes interact with ABO antigens on endothelium, and that the A antigen promotes stronger binding of leukocytes to selectins on the vascular wall, thereby protecting it from enzymatic cleavage and leading to decreased selectin concentrations in serum and elevated concentrations on endothelial cells [19]. These findings may explain the findings of multiple studies linking the A allele to increased risk of MI, vascular disease and venous thromboembolism [20]. In accordance, recently distinct genome-wide association studies linked the ABO gene with MI in the presence of coronary atherosclerosis, with coronary artery disease, with type 2 diabetes and with venous thromboembolism [21–24]. Furthermore, our top SNP tags rs507666, which was the top SNP in GWAS of circulating concentrations of LDL-cholesterol and ICAM-1 [25,26]. In this context, the association of several published loci for atherosclerotic diseases might be mediated by diverse processes that promote inflammation and atherogenesis, and it appears that a substantial subset of risk loci have pleiotropic effects.

Although we excluded the possibility of an analytical interference to explain the association, the exact mechanism linking histoblood group antigen to lower E-selectin concentrations, especially in the context of several candidate biomarker reports that linked lower sE-selectin concentrations with lower incidence of cardiovascular diseases, remains elusive. Among the different hypotheses, it remains possible that sE-selectin bears the A antigen, a modification that might increase its clearance by increasing its affinity for its receptors and/or decrease its secretion from membrane-bound E-selectin. But it is also conceivable that elevated E-selectin levels in high-risk patients represent an epiphenomenon of vessel wall pathology, or a counter-regulatory per se protective mechanism. This is supported by the finding, that in the KORA study population, i.e. apparently healthy, middle-aged subjects, median sE-selectin concentrations were clearly higher than in the LURIC population, i.e. subjects referred to coronary angiography (53.7 ng/ml versus 34.0 ng/ml). Further studies investigating the association between ABO variants and cardiovascular disease, as well as perhaps Mendelian randomization may determine the potentially causal nature of sE-selectin in cardiovascular diseases and provide a more comprehensive assessment of the biological and clinical relevance of the association.

These findings may not only enhance our understanding of adhesion molecule biology, but may also provide a target for several novel research avenues. The increased power to identify variants of small effects, afforded by large sample size and the dense genetic coverage including low-frequency SNPs within loci of interest, has resulted in the identification of associations between previously unreported genes and sE-selectin concentrations, which implicate a regulatory role of histo-blood group antigens in inflammatory adhesion processes.

**Supporting Information**

**Table S1** Study information. (DOC)

**Author Contributions**

Conceived and designed the experiments: WM WK MK BT. Performed the experiments: CM TI DD GS TBG WR. Analyzed the data: JB MEK. Contributed reagents/materials/analysis tools: CM TI DD GS TBG WR. Wrote the paper: BT MK JB WK.

**References**

1. Hansson GK (2005) Inflammation, atherosclerosis and coronary artery disease. N Engl J Med 352: 1685–1695.
2. Leeuwenberg JF, Smeets EF, Neefjes JJ, Shaffer MA, Cinek T, et al. (1992) E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 77: 343–349.
3. Meigo JB, Hu FB, Rifai N, Manson JE (2004) Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 292: 1978–1986.
4. Hwang SJ, Ballantyne CM, Sharratt AR, Smith LC, Davis CE, et al. (1997) Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 96: 4219–4225.
5. Kiechl S, Paré G, Barbatic M, Qi L, Dupuis J, et al. (2001) Association of variation at the ABO locus with circulating levels of soluble intercellular adhesion molecule-1, soluble P-selectin, and soluble E-selectin: a meta-analysis. Circ Cardiovasc Genet 4: 681–686.

6. Löwel H, Doring A, Schneider A, Heier M, Thorand B, et al. (2005) The MONICA Augsburg surveys basin for prospective cohort studies. Gesundheitswesen 67 Suppl 1: 13–18.
7. Koenig W, Karakas M, Zierer A, Herder C, Baumert J, et al. (2011) Oxidized LDL and the risk of coronary heart disease: results from the MONICA/KORA Augsburg Study. J Intern Med 271: 43–50.
8. Karakas M, Koenig W, Zierer A, Herder C, Rottbauer W, et al. (2012) Myeloperoxidase is associated with incident coronary heart disease independently of traditional risk factors: results from the MONICA/KORA Augsburg Study. J Intern Med 271: 43–50.
9. Thorand B, Kolb H, Baumert J, Koenig W, Chamblees L, et al. (2005) Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MONICA/KORA Augsburg Study, 1984–2002. Diabetes 54: 2932–2938.
10. Winkelmann BR, Marz W, Boehm BO, Zott R, Hager J, et al. (2001) Rationale and design of the LURIC study—a resource for functional genomics,
pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics 2(1 Suppl 1): 1–73.

11. World Medical Association Declaration of Helsinki, Ethical Principles for Medical Research involving human subjects. Available: http://www. laakariliitto.fi/e/ethics/helsinki.html. Accessed: 2012 Nov 22.

12. Herder C, Baumert J, Zierer A, Roden M, Meininger C, et al. (2011) Immunological and cardiometabolic risk factors in the prediction of type 2 diabetes and coronary events: MONICA/KORA Augsburg case-cohort study. PLoS ONE 6: e19852.

13. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, et al. (2007) PLINK: a toolset for whole-genome association and population-based linkage analysis. American Journal of Human Genetics 81: 559–575.

14. Saxena R, Elbers CC, Guo Y, Peter I, Gaunt TR, et al. (2011) Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet 90: 410–425.

15. Lanktree MB, Guo Y, Murtaza M, Gleenzer JT, Bailey SD, et al. (2012) Meta-analysis of Dense Gene-centric Association Studies Reveals Common and Uncommon Variants Associated with Height. Am J Hum Genet 80: 6–18.

16. Yamamoto F, Clausen H, White T, Marken J, Hakomori A (1990) Molecular genetic basis of the histo-blood group ABO system. Nature 345: 229–233.

17. Yamamoto F, McNeill PD, Hakomori S (1992) Human histo-blood group A2 transferase coded by A2 allele, one of the A subtypes, is characterized by a single base deletion in the coding sequence, which results in an additional domain at the carboxyl terminal. Biochem Biophys Res Commun 187: 366–374.

18. Barbatic M, Dupuis J, Dehghan A, Bi JC, Hoogeveen RC, et al. (2010) Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. Hum Mol Genet 19: 1863–1872.

19. Ho M, Hickey MJ, Murray AG, Andonegui G, Kubes P (2000) Visualization of Plasmodium falciparum–endothelium interactions in human microvasculature: mimicry of leukocyte recruitment. J Exp Med 192: 1205–1211.

20. Wu O, Bayoumi N, Vickers MA, Clark P (2008) ABO(H) blood groups and vascular disease: a systematic review and meta-analysis. J Thromb Haemost 6: 62–69.

21. Reilly MP, Li M, He J, Ferguson JJ, Stylianou IM, et al. (2011) Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet 377: 383–392.

22. Schunkert H, König IR, Kathiresan S, Reilly MP, Assimes TL, et al. (2011) Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet 43: 333–338.

23. Qi L, Cornelis MC, Kraft P, Jensen M, van Dam RM, et al. (2010) Genetic variants in ABO blood group region, plasma soluble E-selectin levels and risk of type 2 diabetes. Hum Mol Genet 19: 1856–1862.

24. Trégouët DA, Heath S, Saut N, Biron-Andreani C, Schved JP, et al. (2009) Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach. Blood 113: 5298–5303.

25. Smith NL, Chen MH, Dehghan A, Strachan DP, Basu S, et al. (2010) Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation 121: 1382–1392.

26. Chasman DI, Pare G, Mora S, Hespell JC, Peluso G, et al. (2009) Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. PLoS Genet 5: e1000730.